Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Terns Pharmaceuticals (TERN) Equity Average (2020 - 2025)

Terns Pharmaceuticals filings provide 6 years of Equity Average readings, the most recent being $645.3 million for Q4 2025.

  • Quarterly Equity Average rose 81.69% to $645.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $645.3 million through Dec 2025, up 81.69% year-over-year, with the annual reading at $676.2 million for FY2025, 124.94% up from the prior year.
  • Equity Average hit $645.3 million in Q4 2025 for Terns Pharmaceuticals, up from $294.6 million in the prior quarter.
  • Across five years, Equity Average topped out at $645.3 million in Q4 2025 and bottomed at $36.3 million in Q1 2021.
  • Average Equity Average over 5 years is $252.6 million, with a median of $251.5 million recorded in 2023.
  • Peak annual rise in Equity Average hit 325.87% in 2022, while the deepest fall reached 23.0% in 2022.
  • Terns Pharmaceuticals' Equity Average stood at $166.2 million in 2021, then soared by 38.55% to $230.3 million in 2022, then rose by 11.54% to $256.9 million in 2023, then surged by 38.25% to $355.2 million in 2024, then surged by 81.69% to $645.3 million in 2025.
  • Per Business Quant, the three most recent readings for TERN's Equity Average are $645.3 million (Q4 2025), $294.6 million (Q3 2025), and $315.6 million (Q2 2025).